By Andrew M. Evens, Kristie A. Blum
This ebook offers scientific practitioners and the examine neighborhood with unique info at the prognosis, diagnosis, and remedy of non-Hodgkin lymphoma, considering the numerous progress in wisdom together with a number of healing advances which were completed during the last 5-10 years. The paintings is subdivided into epidemiology, pathogenesis, pathology, imaging, and remedy of the non-Hodgkin lymphomas. the whole diversity of healing concepts are tested in line with the most important subtypes of non-Hodgkin lymphoma and the main updated details is equipped on present typical remedies, together with stem cellphone transplantation in addition to new state-of-the-art therapeutics.
Read or Download Non-Hodgkin Lymphoma: Pathology, Imaging, and Current Therapy (Cancer Treatment and Research) PDF
Similar hematology books
This commonly documented, accomplished survey of cell-mediated cytotoxicity (CMC) lines the historical past of killer lymphocytes from 1960 to the current, supplying a definitive source for experts and non-specialists alike. It deals a complicated research of CMC, together with a finished exam of key papers underlying its evolution, and offers a radical dialogue of the newest advances within the box.
Now in its 3rd variation, Molecular Hematology has been completely up to date to include fresh advances in molecular examine. the purpose of the booklet is still a similar – to supply a middle wisdom base for people with little publicity to molecular organic concepts. Molecular biology has had an important impression at the knowing of blood ailments and this e-book exhibits how molecular thoughts can be utilized in analysis and therapy.
Validated given that 1942 because the best hematology textbook, Wintrobe's scientific Hematology is now in its completely revised 12th version. The textual content keeps its culture of correlating uncomplicated technology with the medical perform of hematology and is prepared to aid physicians locate scientific solutions fast and simply.
This e-book presents medical practitioners and the examine group with certain info at the analysis, diagnosis, and therapy of non-Hodgkin lymphoma, making an allowance for the numerous progress in wisdom together with a number of healing advances which have been accomplished during the last 5-10 years.
- Lanzkowsky's Manual of Pediatric Hematology and Oncology, Sixth Edition
- mTOR Inhibition for Cancer Therapy: Past, Present and Future
- The HDL Handbook: Biological Functions and Clinical Implications
- Principles of Molecular Oncology
Additional resources for Non-Hodgkin Lymphoma: Pathology, Imaging, and Current Therapy (Cancer Treatment and Research)
May be predictive of disease burden and indicate risk of progression in IgM MGUS Good biomarker for MCL diagnosis, including cyclin D1-negative variant. May be a useful prognostic parameter, but studies are conflicting. May be a promising prospect for MRD analysis. Suppresses terminal B-cell differentiation and drives angiogenesis in MCL . Prognostic biomarker (worse progression-free and overall survival). Double-protein-positive (MYC and BCL2 protein by immunohistochemistry) independently predicts a worse survival in rituximab–CHOP-treated patients with DLBCL Prognostic and biologically signiﬁcant.
Eur J Cancer 42(15):2570–2576 167. Wang SS, Slager SL, Brennan P, Holly EA, De Sanjose S, Bernstein L et al (2007) Family history of hematopoietic malignancies and risk of non-Hodgkin lymphoma (NHL): a pooled analysis of 10,211 cases and 11,905 controls from the International Lymphoma Epidemiology Consortium (InterLymph). Blood 109(8):3479–3488 168. Zhu K, Levine RS, Brann EA, Gu Y, Caplan LS, Hall I et al (2001) Risk factors for nonHodgkin’s lymphoma according to family history of haematolymphoproliferative malignancies.
Compartmentalizing alveolar sclerosis is a prominent feature in many cases. L. D. Hsi heterogeneous/weak CD30 expression, and MAL antigen. 1, and 8q24 . 13) in PMBL (29/77, 38 %) . The implication of such an aberration might be that the tumor can then escape from immune surveillance by downregulation of HLA class II associated proteins, among other mechanisms. An association was found between CIITA gene fusions, and reduced HLA-DR protein expression was demonstrated . Additional research is needed to identify biomarkers for prognosis in PMBL, though one recent study found MUM1 protein expression to correlate independently with a decreased overall survival .